Trade with Eva : Analytics in action: MCK

Showing posts with label MCK. Show all posts

Tuesday, May 17, 2022

Affirms OXY HPQ positions.

New C ALLY CE PARA CE MCK positions.

Exited WFC BMY ABBV

Highlights from 2022 Q1 filing as compared to Q4 2021:

New positions in: OXY (~136.37 mln shares), HPQ (~104.48 mln), PARA (~68.95 mln), C (~55.16 mln), ALLY (~8.97 mln), CE (~7.88 mln), MCK (~2.92 mln), MKL (~0.42 mln)
Increased positions in: CVX (to ~159.18 mln shares from ~38.25 mln shares), ATVI (to ~64.32 mln from ~14.66 mln), FWONK (to ~7.72 mln from ~2.12 mln), FND (to ~4.78 mln from ~0.84 mln), GM (to ~62.05 mln from ~60 mln) RH (to ~2.17 mln from ~1.82 mln)
Maintained positions in: BAC (~1010.1 mln shares), AAPL (~890.92 mln shares), KO (~400 mln shares), KHC (~325.63 mln shares), AXP (~151.61 mln shares), USB (~126.42 mln shares), DVA (~36.1 mln shares), MCO (~24.67 mln shares)
Closed positions in: BMY (from ~5.2 mln), ABBV (from ~3.03 mln), WFC (from ~0.68 mln)
Decreased positions in: VZ (to ~1.38 mln shares from ~158.82 mln shares), STOR (to ~14.75 mln from ~24.42 mln), RPRX (to ~1.5 mln from ~8.65 mln), KR (to ~57.99 mln from ~61.41 mln)

McKesson misses by $0.11, misses on revs; guides FY17 EPS below consensus :

Reports Q2 (Sep) earnings of $2.94 per share, excluding non-recurring items, $0.11 worse than the Capital IQ Consensus of $3.05; revenues rose 2.5% year/year to $49.96 bln vs the $51.23 bln Capital IQ Consensus.
Co issues downside guidance for FY17, sees EPS of $12.35-12.85 (Prior $13.43-13.93), excluding non-recurring items, vs. $13.55 Capital IQ Consensus Estimate.
- "Our updated outlook for Fiscal 2017 reflects McKesson's expectation of a lower profit contribution resulting from recent customer pricing activities and lower operating profit as a result of further moderating branded pharmaceutical pricing trends compared to previous expectations," said John H. Hammergren, chairman and chief executive officer. "While we work to actively respond to these market forces, we remain focused on our long-term strategy of innovation and value-added solutions. And though we responded quickly to maintain market share and mitigate these pricing challenges, we recognize the near-term impact requires a revision to our outlook."